Format

Send to

Choose Destination
See comment in PubMed Commons below
Dig Dis Sci. 2014 Aug;59(8):1688-97. doi: 10.1007/s10620-014-3058-x. Epub 2014 Feb 27.

Molecular therapies in hepatocellular carcinoma: what can we target?

Author information

1
Division of Transplantation Surgery, Department of Surgery, College of Medicine, University of Kentucky, 800 Rose Street, Room C453, Lexington, KY, 40536-0293, USA.

Abstract

Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.

PMID:
24573715
PMCID:
PMC4344119
DOI:
10.1007/s10620-014-3058-x
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center